17 unknown, 11 recruiting, 9 completed, 1 withdrawn. 10 Not applicable, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 10 | Recruiting 4, Unknown 4, Completed 2 |
| Phase 2 | 5 | Recruiting 3, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Circulating Tumor DNA: new trials by email Literature Review of Circulating Tumor DNA trials Research Report on Circulating Tumor DNA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Danish Vulva Cancer Recurrence Study Measurement of circulating tumor-DNA, Collection of patient-reported outcomes, Algorithmically determined telephone interview with a nurse - Vulva Cancer, Vulva Neoplasm | Not applicable | Recruiting | University of Aarhus | 1295 | 2024-08-15 | 2026-04-29 |
| Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients ctDNA-MRD - Breast Cancer, Neoadjuvant | Unknown | The First Affiliated Hospital with Nanjing Medical University | 50 | 2024-03-08 | 2024-07-24 | |
| ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases Metastatic Colorectal Cancer, Circulating Tumor DNA | Recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 232 | 2024-01-09 | 2025-07-23 | |
| Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology MRD detection - Rectal Adenocarcinoma, Circulating Tumor DNA | Unknown | WeiWei Xiao | 50 | 2023-06-21 | 2023-08-01 | |
| ctDNA Methylation for Epithelial Ovarian Cancer CDO1 and HOXA9 methylation assay - Epithelial Ovarian Cancer, Circulating Tumor DNA | Unknown | Lei Li | 5000 | 2023-03-24 | 2023-04-06 | |
| ctDNA Methylation for Detecting Ovarian Cancer Methylation assay - Epithelial Ovarian Cancer, Circulating Tumor DNA | Unknown | Lei Li | 1400 | 2023-03-24 | 2023-04-06 | |
| Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer circulating tumor DNA - Locally Advanced Rectal Carcinoma, Circulating Tumor DNA | Phase 2 | Recruiting | Peking Union Medical College Hospital | 470 | 2023-02-03 | 2024-12-24 |
| NSCLC Liquid Biopsies and Exhaled VOC Lung Cancer, Circulating Tumor DNA | Recruiting | St. Joseph's Healthcare Hamilton | 210 | 2023-02-01 | 2026-04-22 | |
| Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer detection of ctDNA - Colon Cancer, Circulating Tumor DNA | Not applicable | Recruiting | Peking University Cancer Hospital & Institute | 2684 | 2022-11-01 | 2022-09-07 |
| Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer. Blood sample, Urine sample - Circulating Tumor DNA, Metastatic Prostate Cancer | Completed | University Hospital, Tours | 40 | 2022-08-18 | 2024-03-01 | |
| Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules Local treatment - Advanced Colorectal Cancer, Circulating Tumor DNA | Not applicable | Unknown | Junjie Peng | 100 | 2022-08-01 | 2022-08-10 |
| Using ctDNA to Determine Therapies for Lung Cancer Nivolumab, Pemetrexed, Gemcitabine - Non Small Cell Lung Cancer, Complete Surgical Resection | Phase 2 | Recruiting | University Health Network, Toronto | 66 | 2022-03-28 | 2025-12-18 |
| Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study ctDNA dynamic monitoring - Stage III Colorectal Cancer, Circulating Tumor DNA | Not applicable | Unknown | Fudan University | 316 | 2021-11-01 | 2021-12-17 |
| Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC Adjuvants, Pharmaceutic - Carcinoma, Non-Small-Cell Lung, Next-Generation Sequencing | Unknown | Tang-Du Hospital | 150 | 2021-09-30 | 2021-12-22 | |
| Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) Genomic profiles detection, circulating tumor DNA detection - Lung Cancer, Non-small Cell, EGFR Gene Mutation | Recruiting | Second Xiangya Hospital of Central South University | 210 | 2021-09-28 | 2024-12-02 | |
| CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer High-grade Serous Ovarian Cancer, Circulating Tumor DNA | Recruiting | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 100 | 2021-09-01 | 2026-04-24 | |
| Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization DNA - Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable | Unknown | University Hospital, Rouen | 167 | 2021-05-20 | 2022-05-25 | |
| Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer Blood samples - Breast Cancer, Digestive Cancer | Not applicable | Recruiting | Poitiers University Hospital | 1000 | 2021-03-08 | 2025-12-24 |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease Nivolumab, Vinorelbine, Gemcitabine - Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2021-01-15 | 2022-03-24 | |
| Methylation Analysis of Circulating Tumor DNA in Gastric Cancer Circulating Tumor DNA Methylation Sequencing, tissue DNA Methylation Sequencing - Stomach Neoplasms, Circulating Tumor DNA | Unknown | Shanghai Zhongshan Hospital | 540 | 2020-10-01 | 2020-08-13 |
Showing 20 of 38. Sign in to see all of them.
Breast Neoplasms (6) · Colorectal Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm, Residual (4) · Carcinoma, Ovarian Epithelial (2) · Colonic Neoplasms (2) · Gastrointestinal Neoplasms (2) · Neoplastic Cells, Circulating (2) · Rectal Neoplasms (2) · Carcinoma, Hepatocellular (1) · Digestive System Diseases (1) · Endometrial Neoplasms (1) · Gastrointestinal Diseases (1) · Lung Neoplasms (1) · Neoplasms (1)
Neoplasms (31) · Neoplasms by Site (30) · Digestive System Neoplasms (14) · Digestive System Diseases (13) · Gastrointestinal Diseases (11) · Gastrointestinal Neoplasms (10) · Intestinal Diseases (10) · Intestinal Neoplasms (10) · Colonic Diseases (8) · Rectal Diseases (8) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Breast Diseases (6) · Lung Diseases (6) · Neoplastic Processes (6)
Blood Specimen Collection (4) · Carboplatin (2) · Circulating Tumor DNA (2) · Cisplatin (2) · Gemcitabine (2) · Nivolumab (2) · Pemetrexed (2) · Adjuvants, Pharmaceutic (1) · Chemotherapy, Adjuvant (1) · Control Groups (1) · DNA (1) · Diagnosis-Related Groups (1) · Docetaxel (1) · Fulvestrant (1) · Histone Deacetylase Inhibitors (1)
Fudan University (3) · Poitiers University Hospital (3) · Hunan Cancer Hospital (2) · Karen-Lise Garm Spindler (2) · Lei Li (2) · Peking University Cancer Hospital & Institute (2) · Bristol-Myers Squibb (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dana-Farber Cancer Institute (1) · Foundation Medicine (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · Junjie Peng (1) · National Cancer Center Hospital East (1) · Peking Union Medical College Hospital (1) · Samsung Medical Center (1)
China (16) · France (5) · Denmark (4) · Canada (2) · United States (2) · Japan (1) · Netherlands (1) · South Korea (1) · Taiwan (1)
Aiwen Wu, M.D. (1) · Elizabeth A Mittendorf, MD, PhD (1) · Karen-Lise G Spindler (1) · Matthias Tallegas (1) · Natasha Leighl (1) · Pernille T. Jensen, Professor (1) · Phil Stephens, PhD (1) · Quchang Ouyang, MD (1) · Tao Jiang (1) · Yayi He, MD,PHD (1)
PMID 25444714, PMID 25987569, PMID 26154128, PMID 26311728, PMID 28445469, PMID 29807833, PMID 30400986, PMID 30941670, PMID 31070691, PMID 31621801, PMID 35154704, PMID 35875816, PMID 36518248, PMID 37308396, PMID 39894522, PMID 41435753, PMID 42260101
2018 (1)